{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T05:16:00Z","timestamp":1761714960215,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","primary-care-diabetes.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Primary Care Diabetes"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.pcd.2014.09.002","type":"journal-article","created":{"date-parts":[[2014,11,4]],"date-time":"2014-11-04T21:35:13Z","timestamp":1415136913000},"page":"283-289","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Persistent lipid abnormalities in statin-treated patients: Portuguese diabetic subpopulation of the Dyslipidaemia International Study (DYSIS)"],"prefix":"10.1016","volume":"9","author":[{"given":"Pedro Marques","family":"da Silva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvador Massano","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1623-7382","authenticated-orcid":false,"given":"Ant\u00f3nio Miguel","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcd.2014.09.002_bib0005","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(11)60679-X","article-title":"National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants","volume":"378","author":"Danaei","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.pcd.2014.09.002_bib0010","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/978-1-4614-5441-0_5","article-title":"Global prevalence and future of diabetes mellitus","volume":"771","author":"Ginter","year":"2012","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.pcd.2014.09.002_bib0015","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.diabres.2011.10.029","article-title":"IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030","volume":"94","author":"Whiting","year":"2011","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.pcd.2014.09.002_bib0020","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1464-5491.2010.03017.x","article-title":"First diabetes prevalence study in Portugal: PREVADIAB study","volume":"27","author":"Gardete-Correia","year":"2010","journal-title":"Diabet. Med."},{"key":"10.1016\/j.pcd.2014.09.002_bib0025","series-title":"Diabetes: Factos e n\u00fameros 2013. Relat\u00f3rio Anual do Observat\u00f3rio Nacional da Diabetes 11\/2013","first-page":"10","author":"Gardete Correira","year":"2013"},{"key":"10.1016\/j.pcd.2014.09.002_bib0030","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.2337\/diacare.28.9.2130","article-title":"The burden of mortality attributable to diabetes: realistic estimates for the year 2000","volume":"28","author":"Roglic","year":"2005","journal-title":"Diabetes Care"},{"issue":"Suppl. 2","key":"10.1016\/j.pcd.2014.09.002_bib0035","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1007\/PL00002934","article-title":"Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes","volume":"44","author":"Morrish","year":"2001","journal-title":"Diabetologia"},{"key":"10.1016\/j.pcd.2014.09.002_bib0040","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1753-0407.2011.00161.x","article-title":"Comprehensive diabetes cardiovascular treatment=sugar+blood pressure+lipids","volume":"3","author":"Bloomgarden","year":"2011","journal-title":"J. Diabetes"},{"key":"10.1016\/j.pcd.2014.09.002_bib0045","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1475-2840-8-26","article-title":"Dyslipidemia treatment of patients with diabetes mellitus in a US managed care plan: a retrospective database analysis","volume":"8","author":"Toth","year":"2009","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.pcd.2014.09.002_bib0050","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1001\/archinte.159.22.2661","article-title":"Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study","volume":"159","author":"Haffner","year":"1999","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.pcd.2014.09.002_bib0055","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.2337\/diacare.26.10.2713","article-title":"Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial","volume":"26","author":"Keech","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2014.09.002_bib0060","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.pcd.2014.09.002_bib0065","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.pcd.2014.09.002_bib0070","first-page":"109","article-title":"Vital signs: prevalence, treatment, and control of high levels of low-density lipoprotein cholesterol \u2013 United States, 1999\u20132002 and 2005\u2013200","volume":"60","author":"Centers for Disease Control and Prevention (CDC)","year":"2011","journal-title":"MMWR Morb. Mortal Wkly. Rep."},{"key":"10.1016\/j.pcd.2014.09.002_bib0075","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0140-6736(09)60330-5","article-title":"Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries","volume":"373","author":"Kotseva","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.pcd.2014.09.002_bib0080","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/1741826711400545","article-title":"Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada","volume":"19","author":"Gitt","year":"2012","journal-title":"Eur. J. Prev. Cariol."},{"key":"10.1016\/j.pcd.2014.09.002_bib0085","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1111\/j.1464-5491.2011.03360.x","article-title":"Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study","volume":"28","author":"Leiter","year":"2011","journal-title":"Diabet. Med."},{"key":"10.1016\/j.pcd.2014.09.002_bib0090","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1161\/01.CIR.0000111245.75752.C6","article-title":"Definition of metabolic syndrome. Report of the National Heart, Lung, and Blood Institute\/American Heart Association conference on scientific issues related to definition","volume":"109","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pcd.2014.09.002_bib0095","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/eurheartj\/ehm316","article-title":"Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice: executive summary","volume":"28","year":"2007","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.pcd.2014.09.002_bib0100","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1161\/01.CIR.101.2.207","article-title":"Current perspectives on statins","volume":"101","author":"Maron","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pcd.2014.09.002_bib0105","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00059-006-2829-3","article-title":"ESH-ESC guidelines for the management of hypertension","volume":"31","author":"Erdine","year":"2006","journal-title":"Herz"},{"key":"10.1016\/j.pcd.2014.09.002_bib0110","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case\u2013control study","volume":"364","author":"Yusuf","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.pcd.2014.09.002_bib0115","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11892-008-0013-2","article-title":"Diabetic dyslipidemia and atherosclerosis: evidence from clinical trials","volume":"8","author":"Farmer","year":"2008","journal-title":"Curr. Diab. Rep."},{"key":"10.1016\/j.pcd.2014.09.002_bib0120","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.pcd.2014.09.002_bib0125","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). ESC\/EAS Guidelines for the management of dyslipidaemias","volume":"32","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.pcd.2014.09.002_bib0130","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.recesp.2010.10.030","article-title":"Prevalence and characteristics of lipid abnormalities in patients treated with statins in primary and secondary prevention in Spain. DYSIS-Spain study","volume":"64","author":"Gonz\u00e1lez-Juanatey","year":"2011","journal-title":"Rev. Esp. Cardiol."},{"key":"10.1016\/j.pcd.2014.09.002_bib0135","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00508-011-0057-1","article-title":"Persistent dyslipidemia in Austrian patients treated with statins for primary and secondary prevention of atherosclerotic events \u2013 results of the DYSlipidemia International Study (DYSIS)","volume":"123","author":"Drexel","year":"2011","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.pcd.2014.09.002_bib0140","first-page":"47","article-title":"Persistent lipid abnormalities in patients treated with statins: Portuguese results of the Dyslipidemia International Study (DYSIS)","volume":"30","author":"da Silva","year":"2011","journal-title":"Rev. Port. Cardiol."},{"key":"10.1016\/j.pcd.2014.09.002_bib0145","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11845-011-0702-8","article-title":"Prevalence of dyslipidaemia in statin-treated patients in Ireland: Irish results of the DYSlipidaemia International Study (DYSIS)","volume":"180","author":"Horgan","year":"2011","journal-title":"Ir. J. Med. Sci."},{"key":"10.1016\/j.pcd.2014.09.002_bib0150","first-page":"e330","article-title":"Prevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia International Study (DYSIS)","volume":"26","author":"Goodman","year":"2010","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.pcd.2014.09.002_bib0155","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/HJR.0b013e3283383f30","article-title":"EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries","volume":"17","author":"Kotseva","year":"2010","journal-title":"Eur. J. Cardiovasc. Prev. Rehabil."},{"key":"10.1016\/j.pcd.2014.09.002_bib0160","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.amjmed.2005.11.015","article-title":"Contemporary management of dyslipidemia in high-risk patients: targets still not met","volume":"119","author":"Yan","year":"2006","journal-title":"Am. J. Med."},{"key":"10.1016\/j.pcd.2014.09.002_bib0165","first-page":"297","article-title":"Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in Canada","volume":"26","author":"Braga","year":"2010","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.pcd.2014.09.002_bib0170","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ejim.2013.07.005","article-title":"Attainment of normal lipid levels among high cardiovascular risk patients: pooled analysis of observational studies from the United Kingdom, Sweden, Spain and Canada","volume":"24","author":"Ambegaonkar","year":"2013","journal-title":"Eur. J. Intern. Med."}],"container-title":["Primary Care Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1751991814001028?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1751991814001028?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T23:55:16Z","timestamp":1761695716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1751991814001028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S1751991814001028"],"URL":"https:\/\/doi.org\/10.1016\/j.pcd.2014.09.002","relation":{},"ISSN":["1751-9918"],"issn-type":[{"type":"print","value":"1751-9918"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Persistent lipid abnormalities in statin-treated patients: Portuguese diabetic subpopulation of the Dyslipidaemia International Study (DYSIS)","name":"articletitle","label":"Article Title"},{"value":"Primary Care Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcd.2014.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}